Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma : the ARON-2 study
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
BACKGROUND: The advent of immune-checkpoint inhibitors has challenged previous treatment paradigms for advanced urothelial carcinoma (UC) in the post-platinum setting as well as in the first-line setting for cisplatin-ineligible patients. In this study, we investigated the effectiveness of pembrolizumab as first-line treatment for cisplatin-ineligible UC.
METHODS: Data from patients aged ≥ 18 years with cisplatin-ineligible UC and receiving first-line pembrolizumab from January 1st 2017 to September 1st 2022 were collected. Cisplatin ineligibility was defined according to the Galsky criteria. Thirty-three Institutions from 18 countries were involved in the ARON-2 study.
RESULTS: Our analysis included 162 patients. The median follow-up time was 18.9 months (95%CI 15.3-76.9). In the overall study population, the median OS was 15.8 months (95%CI 11.3-32.4). The median OS was significantly longer in males versus females while no statistically significant differences were observed between patients aged < 65y versus ≥ 65y and between smokers and non-smokers. According to Recist 1.1 criteria, 26 patients (16%) experienced CR, 32 (20%) PR, 39 (24%) SD and 55 (34%) PD.
CONCLUSIONS: Our data confirm the role of pembrolizumab as first-line therapy for cisplatin-unfit patients. Further studies investigating the biological and immunological characteristics of UC patients are warranted in order to optimize the outcome of patients receiving immunotherapy in this setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Cancer immunology, immunotherapy : CII - 72(2023), 9 vom: 16. Sept., Seite 2961-2970 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
ARON-2 study |
|---|
| Anmerkungen: |
Date Completed 11.08.2023 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00262-023-03469-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357505972 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357505972 | ||
| 003 | DE-627 | ||
| 005 | 20240426233211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-023-03469-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM357505972 | ||
| 035 | |a (NLM)37248424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santoni, Matteo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma |b the ARON-2 study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2023 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a BACKGROUND: The advent of immune-checkpoint inhibitors has challenged previous treatment paradigms for advanced urothelial carcinoma (UC) in the post-platinum setting as well as in the first-line setting for cisplatin-ineligible patients. In this study, we investigated the effectiveness of pembrolizumab as first-line treatment for cisplatin-ineligible UC | ||
| 520 | |a METHODS: Data from patients aged ≥ 18 years with cisplatin-ineligible UC and receiving first-line pembrolizumab from January 1st 2017 to September 1st 2022 were collected. Cisplatin ineligibility was defined according to the Galsky criteria. Thirty-three Institutions from 18 countries were involved in the ARON-2 study | ||
| 520 | |a RESULTS: Our analysis included 162 patients. The median follow-up time was 18.9 months (95%CI 15.3-76.9). In the overall study population, the median OS was 15.8 months (95%CI 11.3-32.4). The median OS was significantly longer in males versus females while no statistically significant differences were observed between patients aged < 65y versus ≥ 65y and between smokers and non-smokers. According to Recist 1.1 criteria, 26 patients (16%) experienced CR, 32 (20%) PR, 39 (24%) SD and 55 (34%) PD | ||
| 520 | |a CONCLUSIONS: Our data confirm the role of pembrolizumab as first-line therapy for cisplatin-unfit patients. Further studies investigating the biological and immunological characteristics of UC patients are warranted in order to optimize the outcome of patients receiving immunotherapy in this setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ARON-2 study | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a NCT05290038 | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Real-world data | |
| 650 | 4 | |a Urothelial cancer | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Myint, Zin W |e verfasserin |4 aut | |
| 700 | 1 | |a Büttner, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Takeshita, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Yohei |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Elaine T |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Danielle |e verfasserin |4 aut | |
| 700 | 1 | |a Küronya, Zsófia |e verfasserin |4 aut | |
| 700 | 1 | |a Tural, Deniz |e verfasserin |4 aut | |
| 700 | 1 | |a Pichler, Renate |e verfasserin |4 aut | |
| 700 | 1 | |a Grande, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Crabb, Simon J |e verfasserin |4 aut | |
| 700 | 1 | |a Kemp, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Massari, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Scagliarini, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Iacovelli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Vau, Nuno |e verfasserin |4 aut | |
| 700 | 1 | |a Basso, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Maruzzo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Molina-Cerrillo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Bamias, Aristotelis |e verfasserin |4 aut | |
| 700 | 1 | |a De Giorgi, Ugo |e verfasserin |4 aut | |
| 700 | 1 | |a Zucali, Paolo Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Mimma |e verfasserin |4 aut | |
| 700 | 1 | |a Seront, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Popovic, Lazar |e verfasserin |4 aut | |
| 700 | 1 | |a Caffo, Orazio |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Sebastiano |e verfasserin |4 aut | |
| 700 | 1 | |a Kanesvaran, Ravindran |e verfasserin |4 aut | |
| 700 | 1 | |a Kopecky, Jindrich |e verfasserin |4 aut | |
| 700 | 1 | |a Kucharz, Jakub |e verfasserin |4 aut | |
| 700 | 1 | |a Zeppellini, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Fiala, Ondřej |e verfasserin |4 aut | |
| 700 | 1 | |a Landmesser, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Ansari, Jawaher |e verfasserin |4 aut | |
| 700 | 1 | |a Giannatempo, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Zabalza, Ignacio Ortego |e verfasserin |4 aut | |
| 700 | 1 | |a Monteiro, Fernando Sabino M |e verfasserin |4 aut | |
| 700 | 1 | |a Battelli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrò, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Porta, Camillo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology, immunotherapy : CII |d 1982 |g 72(2023), 9 vom: 16. Sept., Seite 2961-2970 |w (DE-627)NLM012922226 |x 1432-0851 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:9 |g day:16 |g month:09 |g pages:2961-2970 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00262-023-03469-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 9 |b 16 |c 09 |h 2961-2970 | ||